FCF Healthcare & Life Sciences Venture Capital Monitor – USA – 06/2024 published - FCF Fox Corporate Finance GmbH

FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Healthcare & Life Sciences Venture Capital Monitor – USA – 06/2024”.

The Monitor is a monthly published overview of venture capital trends in the US Healthcare & Life Sciences sector.

As of the end of June 2024 we identified the following current VC trends in the United States:

• Total Healthcare & Life Sciences funding reached EUR 18,355m
• Biotech received 53% of the total investment volume (EUR 9,700m) with oncology being the leading indication (26%)
• TechBio is one of the strongest growth segments securing 11% of the total YTD investment volume
• In June Formation Bio secures the highest transaction volume with EUR 345m, followed by Enveda Biosciences with EUR 161m and Marea Therapeutics with EUR 148m
• ARCH Venture Partners (United States) is the most active investor (by deal volume), followed by RA Capital Management (United States) and GV (Google Ventures / United States)

To access the full report, please click here.